Press Release Archive

January 27, 2012 - U.S. Food And Drug Administration Approves Pfizer’s INLYTA® (axitinib) For Patients With Previously Treated Advanced Renal Cell Carcinoma (RCC)

(BUSINESS WIRE)--Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved INLYTA® (axitinib), a kinase inhibitor, for the treatment of patients with advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy. The approval is based on data from the Phase 3 AXIS trial, which demonstrated that INLYTA significantly extended progression free survival (PFS) [HR=0.67, 0.54-0.81, P<0.0001] withmore...

January 26, 2012 - Pfizer Announces FDA Acceptance Of New Drug Application For Bosutinib For Patients With Previously Treated Ph+ Chronic Myeloid Leukemia

(BUSINESS WIRE)--Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for standard review of bosutinib as a treatment option for adult patients with previously treated Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML). This submission was based on efficacy and safety data from Study 200, a single-arm study of bosutinib in over 500 patients with previouslymore...

January 25, 2012 - Alzheimer's Challenge 2012: Seeking New Tools To Help Improve Alzheimer’s Care

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE), together with its collaborator on the Alzheimer’s Immunotherapy Program (AIP), Janssen Alzheimer Immunotherapy, and the Geoffrey Beene Gives Back® Alzheimer’s Initiative today introduced the Alzheimer’s Challenge 2012 at the Care Innovations Summit in Washington, D.C. The Alzheimer’s Challenge 2012 calls for inventive concepts to help improve the diagnostic identification and tracking of Alzheimer’smore...

January 22, 2012 - MS LifeLines® Earns J.D. Power and Associates Call Center Certification for Customer Service Excellence in Providing Support Services to the MS Community

ROCKLAND, Mass. & NEW YORK--(BUSINESS WIRE)--ROCKLAND, Mass.more...

January 16, 2012 - Medivation and Pfizer Announce Results from Phase 3 Concert Trial of Dimebon in Alzheimer’s Disease

(BUSINESS WIRE)--SAN FRANCISCO

January 9, 2012 - Introducing nutritionpossible.com – A New Resource That Offers Personalized Nutritional Guidance to Achieve Better Health

(BUSINESS WIRE)--Millions of resolutions come with every New Year, many of which are to get healthy. But, there’s a lot of confusion around what constitutes healthy nutrition, which is a key piece of the puzzle. Now, there’s an easy and free solution to help make sound nutritional choices to help people keep their resolutions throughout the year. Today, the makers of Centrum® multivitamins announce the launch of nutritionpossible.com, a

January 3, 2012 - Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference

(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a presentation by Ian Read, Chairman of the Board and Chief Executive Officer, at the 30th Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2012 at 8:00 a.m. Pacific Standard Time. To view and listen to the webcast, visit our web site at www.pfizer.com and click on the “30th Annual J.P. Morgan Healthcare

December 30, 2011 - Pfizer Receives FDA Approval to Extend Use of Prevnar 13® for Prevention of Pneumococcal Pneumonia and Invasive Disease in Adults 50 Years and Older

(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has granted approval of the Company’s pneumococcal conjugate vaccine Prevnar 13®* (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) as a single dose for use in adults. Prevnar 13 is indicated for adults 50 years of age and older for active immunization for the prevention of pneumonia and invasive disease caused by the

December 21, 2011 - Pfizer Reports Results From Three Phase 4 Studies Demonstrating EMBEDA® (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules CII Impact On Drug Liking And Withdrawal Symptoms

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today results from three Phase 4 studies of EMBEDA® (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules CII designed to assess the effect of the drug when crushed and taken either orally or intranasally. Studies ALO-01-10-4005 and ALO-01-10-4004 were double-blind cross-over designed studies in non-dependent, recreational opioid users that compared subjective

December 19, 2011 - Pfizer Invites Public To View And Listen To Webcast Of January 31 Conference Call With Analysts

(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EST on Tuesday, January 31, 2012. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Fourth Quarter 2011 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our

December 19, 2011 - Pfizer Announces FDA Acceptance For Review Of New Drug Application For Tofacitinib For Adult Patients With Moderately To Severely Active Rheumatoid Arthritis

(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for tofacitinib (development code CP-690,550), an investigational novel, oral JAK inhibitor being studied for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA). The FDA has provided an anticipated Prescription Drug User Fee Act (PDUFA) action

December 15, 2011 - Pfizer Reports Positive Results From Phase 3 Trial Of Lyrica (pregabaline) Capsules CV In Restless Legs Syndrome

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that a Phase 3 study for Lyrica (pregabalin) in patients with Restless Legs Syndrome (RLS) met each of its three co-primary endpoints, showing significant benefit as compared with placebo and pramipexole. Pfizer will continue to further analyze these top-line results. The study, A0081186, was a randomized, double-blind, 12-month trial. It enrolled more than 700 patients, who

December 15, 2011 - Pfizer Broadens and Extends Commitment to Help Prevent Pneumococcal Disease in Infants and Young Children in the World’s Poorest Countries

(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced it has entered into a second supply agreement which will broaden and extend the duration of the Company’s commitment to help protect millions of infants and young children in the developing world from pneumococcal disease – the leading cause of vaccine-preventable death in young children. Pfizer is now committed to supply up to a total of 480 million doses of Prevenar 13* (Pneumococcal

December 12, 2011 - New Survey Reveals Top Misperceptions Parents Have When Treating Their Child’s Fever

(BUSINESS WIRE)--Tis’ the season for sneezing, coughing and fevers. As the temperature drops and cold and flu season gets under way, parental anxiety is expected to rise. According to two new surveys of parents and pediatricians from Pfizer Consumer Healthcare, makers of Children’s Advil®, more than half of all parents report feeling anxious, fearful or helpless when their child comes down with a fever. In addition, many parents are not

December 12, 2011 - Pfizer Elects CEO Ian Read As Chairman Of The Board

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its Board of Directors has elected current President and Chief Executive Officer, Ian Read, as Chairman of the Board and Chief Executive Officer, effective immediately. Mr. Read succeeds George Lorch as Chairman of the Board. The independent members of the board named Mr. Lorch as Lead Independent Director. “Over the past year, Ian has clearly demonstrated the leadership

December 12, 2011 - Pfizer Declares A 22-Cent First-Quarter 2012 Dividend

(BUSINESS WIRE)--The board of directors of Pfizer Inc. (NYSE: PFE) today declared a 22-cent first-quarter 2012 dividend on the company’s common stock, payable March 6, 2012, to shareholders of record at the close of business on February 3, 2012. Pfizer increased the dividend by 10 percent, to 22 cents from 20 cents per share. The first-quarter 2012 cash dividend will be the 293rd consecutive quarterly dividend paid by Pfizer

December 8, 2011 - Jon Bon Jovi Reveals His True Advil® Story

(BUSINESS WIRE)--Jon Bon Jovi’s schedule is packed - on any given day he’s performing sold-out stadium shows, staying fit with daily runs, spending time with his family and giving back through the Jon Bon Jovi Soul Foundation. One thing that’s not on his schedule is pain. The artist gives a glimpse into his life in a new advertisement for Advil®. The TV ad was shot in Red Bank, New Jersey, at the Jon Bon Jovi Soul Kitchen, a community

December 7, 2011 - The Advil® Congestion Relief Project Tackles Congestion in Chicago, the Country’s #1 City for Traffic Congestion*

(BUSINESS WIRE)--Pfizer Consumer Healthcare, the makers of Advil® Congestion Relief, stopped in Westside Chicago yesterday as part of a nationwide effort to help communities fight congestion. Chicago ranks #1 in the country for traffic congestion*, and to help alleviate congestion on busy roads this winter, Advil® Congestion Relief donated snow removal equipment specifically for the newly-established protected bicycle lanes, an

December 7, 2011 - FDA Advisory Committee Finds The Benefit/Risk Profile Of Axitinib In Previously Treated Advanced Renal Cell Carcinoma (RCC) To Be Favorable

(BUSINESS WIRE)--Pfizer Inc. announced today that the U.S. Food and Drug Administration’s (FDA’s) Oncologic Drugs Advisory Committee (ODAC) voted unanimously 13 to 0 that data for the investigational agent axitinib support a favorable benefit/risk profile for the treatment of patients with advanced renal cell carcinoma (RCC) after failure of a first-line systemic therapy. The ODAC panel’s recommendation will be considered by the FDA when

December 5, 2011 - Pfizer’s Toviaz Shows Positive Top-Line Primary Endpoint Result In Study Of Overactive Bladder In Vulnerable Elderly Patients

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today the top-line primary endpoint result for Toviaz (fesoterodine fumarate) Study A0221049 – Efficacy and Safety of Fesoterodine Flexible Dose Regimen in Vulnerable Elderly Patients with Overactive Bladder. The study met its primary endpoint: treatment with Toviaz was found to be statistically significantly superior to placebo in reducing the mean number of urgency urinary incontinence (UUI

Press release archive foot note

Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.

Stay on top of Pfizer breaking news: Get News Alerts by RSS.

Stock Quote Disclaimer

20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.

If you do not have Adobe^® Reader, download it here. It is available without charge from Adobe^®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page.